Back to search results

Percepta for Mild Cognitive Impairment

This study is testing a plant-based dietary supplement called Percepta, which contains cat's claw and oolong tea extract, for people aged 40 to 85 with self-reported mild cognitive impairment (MCI). Researchers want to see if Percepta can improve thinking and memory. Another group will receive a placebo (an inactive substance) to compare results. The main goal is to measure changes in your cognitive (thinking) ability using a digital test called MoCA over six months. The study is currently unclear on its recruitment status and plans to enroll 154 participants.

Study design
This is a Phase 1, randomized, double-blind study, meaning participants are randomly assigned to either Percepta or placebo, and neither you nor the researchers will know which you are receiving. About 154 people will participate.
What's involved
You would take the study supplement or placebo by mouth once daily for 6 months. Your cognitive performance will be assessed using a digital MoCA test at the start, at 3 months, and at 6 months.
Compensation
Not stated in the trial record.
Follow-up
Your cognitive performance will be measured at 3 months and 6 months after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07612449

Percepta for Cognitive Optimization

Not Yet Recruiting
NAAges 40–85InterventionalPrevention
Cerebrum DAO Association
~154 participants
Updated 2026-05-28 on ClinicalTrials.gov
What's tested:PerceptaPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Digital MoCA Scores
Measured over Baseline (Month 0), Month 3, and Month 6

Conditions

Mild Cognitive Impairment (MCI)
Memory

Explore related trials

Mild cognitive disorder

NCT07612449

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Reputable Health

    Wilmington, Delawareno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Mackenzie De Jesus, DHSc, MS
[email protected]
754-301-9531
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Demographics: Must be English-speaking and currently residing in the United States.
Cognitive Status: Must have self-reported cognitive impairment, defined specifically by a Montreal Cognitive Assessment (MoCA) score of less than 25.
Technology Access: Must own an Oura Ring, maintain an active membership throughout the study, and have consistent access to a smartphone for app-based surveys and data syncing.
Medical Stability: Must be in good general health and medically stable, with no significant health changes in the three months prior to enrollment.
Consent and Compliance: Must provide signed informed consent and demonstrate a willingness to comply with all study procedures, including assessments and lifestyle considerations.

Exclusion

Neurological and Psychiatric Disorders: A self-reported diagnosis of dementia, Alzheimer's disease, Parkinson's disease, depressive disorders, bipolar disorder, schizophrenia, epilepsy, multiple sclerosis, or substance use disorder. This also includes a history of stroke, traumatic brain injury (TBI), intracranial hemorrhage, or seizure disorders.
Medication Use: Current use of cognitive-affecting medications or supplements, such as donepezil, memantine, methylphenidate, benzodiazepines, antipsychotics, or nootropics.
Allergies: Known allergy or sensitivity to cat's claw or oolong tea,. Reproductive Status: Currently pregnant, breastfeeding, or planning to become pregnant within the next 12 months.
Genetic Risk: Known carrier of the APOE-4 allele.
Recent Study Participation: Enrollment in another clinical trial or intervention study within the past 30 days.

What this trial measures

  • Change in Digital MoCA ScoresBaseline (Month 0), Month 3, and Month 6

    Unit: Points on MoCA scale (0-30) The Digital MoCA (eMoCA) is a validated, tablet-based version of the standard MoCA screening tool used to assess global cognitive function and detect mild cognitive impairment (MCI). The assessment evaluates multiple cognitive domains, including memory, executive function, visuospatial skills, attention, language, and orientation. Total scores range from 0 to 30, with higher scores indicating better cognitive performance. The primary analysis evaluates the change in MoCA scores between the Percepta intervention group and the placebo group from baseline to the 6-month-endpoint. Additional analyses will assess the percent change from baseline and the proportion of participants achieving a Minimal Clinically Important Difference (MCID), defined as a ≥2-point improvement.